Novartis Ag (NVSEF) EPS (Basic) (2009 - 2025)

Novartis Ag has disclosed EPS (Basic) across 15 years of filings, most recently posting $2.31 for Q2 2025.

• EPS (Basic) for Q2 2025 came in at $2.31, down 52.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.31 (down 83.03% YoY), and the FY2025 annual result was $18.26, up 21.24% from the prior year.
• EPS (Basic) came in at $2.31 for Q2 2025 at Novartis Ag, down from $8.79 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $8.79 in Q4 2024 to a low of $0.05 in Q2 2023.
• The 5-year median for EPS (Basic) is $0.66 (2022), against an average of $2.11.
• Across the five-year window, EPS (Basic) slumped 100.0% in 2021 and soared 9508.21% in 2024, its largest moves.
• Novartis Ag's EPS (Basic) stood at $6.61 in 2021, then slumped by 98.92% to $0.07 in 2022, then advanced by 28.41% to $0.09 in 2023, then jumped by 9508.21% to $8.79 in 2024, then tumbled by 73.67% to $2.31 in 2025.
• The last three EPS (Basic) figures came in at $2.31 (Q2 2025), $8.79 (Q4 2024), and $4.84 (Q2 2024), per Business Quant data.